Sol Gel Technologies Ltd (SLGL) Receives $19.00 Average Price Target from Analysts
Sol Gel Technologies Ltd (NASDAQ:SLGL) has been given an average recommendation of “Buy” by the six analysts that are presently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $19.00.
SLGL has been the subject of a number of research analyst reports. ValuEngine raised shares of Sol Gel Technologies from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Zacks Investment Research downgraded shares of Sol Gel Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, May 19th. Finally, HC Wainwright assumed coverage on shares of Sol Gel Technologies in a research note on Monday, July 16th. They set a “buy” rating and a $21.00 price target for the company.
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Point72 Asset Management L.P. bought a new stake in shares of Sol Gel Technologies during the first quarter worth approximately $103,000. DAFNA Capital Management LLC bought a new stake in shares of Sol Gel Technologies during the first quarter worth approximately $361,000. Guggenheim Capital LLC bought a new stake in Sol Gel Technologies in the first quarter valued at approximately $1,073,000. Delek Group Ltd. increased its stake in Sol Gel Technologies by 22.3% in the second quarter. Delek Group Ltd. now owns 1,269,816 shares of the company’s stock valued at $9,803,000 after purchasing an additional 231,786 shares in the last quarter. Finally, Nexthera Capital LP bought a new stake in Sol Gel Technologies in the first quarter valued at approximately $5,334,000. 22.32% of the stock is owned by institutional investors and hedge funds.
Sol Gel Technologies (NASDAQ:SLGL) last announced its earnings results on Wednesday, August 8th. The company reported ($0.36) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.48) by $0.12. The company had revenue of $0.05 million during the quarter, compared to the consensus estimate of $0.05 million. sell-side analysts anticipate that Sol Gel Technologies will post -2.05 EPS for the current year.
Sol Gel Technologies Company Profile
Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris; and VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea.
See Also: What is a Leveraged Buyout (LBO)?
Receive News & Ratings for Sol Gel Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sol Gel Technologies and related companies with MarketBeat.com's FREE daily email newsletter.